Clinical Research Directory
Browse clinical research sites, groups, and studies.
4 clinical studies listed.
Filters:
Tundra lists 4 Myelodysplastic-Myeloproliferative Diseases clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT02808858
Italian Network MDS Registry
Epidemiological data collection of adult patients affected by myelodysplastic syndrome (MDS) newly diagnosed.
Gender: All
Ages: 18 Years - 106 Years
Updated: 2026-09-04
7 states
NCT03434730
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
The aim of the research in this study is to make participants' transplant safer by reducing the risk of developing GVHD and GVHD-related complications by giving participants a dose of the drug tocilizumab in addition to the standard approach for GVHD prevention. Tocilizumab reduces the risk of inflammation by blocking the effect of Interleukin-6, a protein that exists in high levels in the blood when there is inflammation. Participants who receive stem cell transplants have high levels of this protein in their blood early after transplant. Therefore, the goal of this study is to reduce the risk of inflammation after transplant with the addition of Tocilizumab. This could decrease the risk of developing GVHD and GVHD-associated complications.
Gender: All
Ages: 18 Years - 65 Years
Updated: 2026-05-26
1 state
NCT05969821
Clonal Hematopoiesis of Immunological Significance
Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.
Gender: All
Ages: 18 Years - Any
Updated: 2026-03-23
NCT02760238
Myeloproliferative Neoplasms (MPNs) Patient Registry
The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.
Gender: All
Updated: 2024-08-27
1 state